All Search Results
News Releases
Feb 24, 2026, 16:15 ET HOTH THERAPEUTICS ACCELERATES HT-001 TRIAL ENROLLMENT WITH NEW CLINICAL SITE AS PATIENT DEMAND INCREASES
meaningful reductions in pain and itchingZero dose-limiting toxicities observed across the entire trial to dateAt the American Academy of Dermatology Annual Meeting, a case study demonstrated complete lesion and symptom resolution after just one week of twice-daily application in a metastatic
More news about: Hoth Therapeutics, Inc.
Feb 19, 2026, 08:14 ET SciBase's Nevisense (EIS) Included in the US NCCN Guidelines for Melanoma which supports the use of EIS in the detection of melanoma
judgment," said Dr. Darrell Rigel, MD, Clinical Professor of Dermatology at the New York University (NYU), and Past President of the American Academy of Dermatology. "While visual assessment and dermoscopy have long been shown to improve melanoma detection rates, our published clinical research demonstrates
More news about: SciBase
Feb 18, 2026, 06:45 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
associated with poorer treatment response to biologics at 6 months: A prospective analysis in Corrona Psoriasis Registry. Journal of the American Academy of Dermatology, Volume 86, Issue 1, 68 - 76.4 Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab
More news about: Eli Lilly and Company
Jan 22, 2026, 10:07 ET Ezderm Unveils Platform Evolution: Introduces 'Eve' AI Ecosystem and 'Compass' Clinical Interface
Debuting this March at the 2026 American Academy of Dermatology (AAD) Annual Meeting, Eve is a proprietary AI ecosystem fully embedded in the Ezderm EHR and Practice Management platform. From encounter
More news about: Ezderm, LLC
Jan 20, 2026, 07:00 ET Clinical Trial Demonstrates Accurate Non-Invasive Detection of In Vivo Biologic Activity in Melanomas by the Orlucent® Skin Fluorescent Imaging System
solutions for the non-invasive detection of melanoma activity, were published in the February edition of the peer-reviewed Journal of the American Academy of Dermatology (JAAD) International.
More news about: Orlucent, Inc.
